Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access of Iressa (Gefitinib) in Advanced NSCLC
NCT00034879Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2000
- Primary completion
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Aug 2000; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00034879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034879.